Answers are grounded in this paper and cite their sources.
OBJECTIVES: T cells in blood and tumor of one LELC patient positive for EBV infection in lung tumor cells. METHODS: T cells at the transcriptomic and phenotypic levels in blood and tumor tissues of the LELC patient. RESULTS: tumor-infiltrating lymphocytes (TILs) mostly did not express PD-1. CONCLUSION: TILs in EBV-driven tumor are heterogeneous and partially lack PD-1 expression, suggesting that anti-PD1/PD-L1 immunotherapy may not be an appropriate strategy for disinhibiting EBV-specific cells in the treatment of LELC patients.
No takes yet. Share an insight, caveat, or question.
Simoni et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: